SNIPR Biome ApS

The European Commission’s proposal to use transferable exclusivity vouchers as a way of encouraging companies to develop new antimicrobial drugs has drawn praise and criticism in equal measure. For so

The Novo Nordisk Foundation and the Broad Institute introduced a new Center for Genomic Mechanisms of Disease research unit on 15 September, to be housed at the Harvard University / Massachusetts I

Denmark-based SNIPR Biome ApS has developed a CRISPR/Cas 3 approach to precisely target bacteria like E. coli to prevent infections without harming the beneficial bacteria in the patient’s microbi

Danish biotech ADCendo ApS believes it can create a pipeline of antibody-drug conjugates targeting the novel cancer target uPARAP, bringing a lead candidate into clinical trials probably by 2023 usi